| Aug 7 |
I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)
|
| Jul 15 |
I-Mab announces CEO transition
|
| Jul 15 |
I-Mab Announces Leadership Transitions
|
| Jun 7 |
While private equity firms own 21% of I-Mab (NASDAQ:IMAB), retail investors are its largest shareholders with 59% ownership
|
| Jun 6 |
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
|
| Jun 6 |
I-Mab and BMS assess givastomig for gastric and oesophageal cancer
|
| Jun 5 |
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers
|
| May 23 |
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024
|
